WG
KYMR icon

Winton Group’s Kymera Therapeutics KYMR Stock Holding History

Winton Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,384
Closed -$397K – 1016
2022
Q1 		$397K Buy
9,384
+2,441
+35% +$103K 0.02% 743
2021
Q4 		$441K Sell
6,943
-935
-12% -$54.5K 0.03% 707
2021
Q3 		$463K Buy
7,878
+2,305
+41% +$134K 0.03% 898
2021
Q2 		$270K Buy
+5,573
New +$242K 0.01% 1241

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Winton Group's KYMR Position: Q2 2022 in Review

Winton Group sold out of Kymera Therapeutics (KYMR) in Q2 2022, closing a stake of 9,384 shares — an estimated $397K sold.

Winton Group first reported a position in KYMR in Q2 2021 and held it in 4 quarters. The position peaked at $463K in Q3 2021. 100 funds tracked by Wall St. Rank hold KYMR as of Q2 2022.

  • Winton Group reported no remaining Kymera Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Winton Group sold 9,384 Kymera Therapeutics shares in Q2 2022, an estimated $397K.
  • Winton Group first reported a position in Kymera Therapeutics in Q2 2021 and held it in 4 quarters.
  • Winton Group's Kymera Therapeutics position peaked at $463K in Q3 2021.
  • 100 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2022.

Based on Winton Group's 13F filing for Q2 2022, filed 10 Aug 2022.